Pheochromocytoma is a rare adrenal gland tumor that may precipitate life-threatening hypertension.
It can occur at any age but usually occurs during young to mid-adult life.
Majority of patients presents with ≥1 of the following hypertension resistant to standard antihypertensive treatment, hypertensive crisis with malignant hypertension, hypertensive encephalopathy, aortic dissection, or myocardial infarction and paroxysmal symptoms which suggest seizure disorder, anxiety attacks or hyperventilation.
Atrial fibrillation (AF) carries an excess risk of stroke recurrence independent of comorbidity with and heart failure (HF), while HF without AF also poses a significant risk of recurrence, a study has shown.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.